The clinical trials of anti-Covid-19 intravenous immunoglobulin (C-IVIG), developed by the Dow University of Health Sciences (DUHS) for treating the novel coronavirus, has shown encouraging results, claimed the varsity on Saturday. According to a DUHS statement, the administration of C-IVIG to patients with severe infection has led to a 100 per cent recovery rate while […]